Gamma-delta T cell therapy
Cell therapies built from a rare T-cell type that recognises stressed cancer cells without needing tissue matching, making them candidates for off-the-shelf products.
Overview
Gamma-delta T cells recognise stress ligands and phosphoantigens on tumour cells independently of HLA, so donor cells can be given without matching and without causing graft-versus-host disease. Companies expand the Vδ1 or Vδ2 subsets from healthy donors, sometimes adding a CAR, and early trials in leukaemia, lymphoma and solid tumours are under way. Persistence after infusion and manufacturing scale are the main hurdles.
How it works
Donor gamma-delta T cells are expanded ex vivo with phosphoantigens or cytokines, optionally engineered with a chimeric antigen receptor, and infused as an allogeneic product.
- HLA-independent recognition, no graft-versus-host disease
- Off-the-shelf potential
- Innate-like killing of stressed cells
- Short persistence
- Early clinical stage
- Expansion yields vary between donors
Latest papers
topQuery for this technology: (TITLE:"Gamma-delta T cell therapy" OR ABSTRACT:"Gamma-delta T cell therapy") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Gamma-delta T cell therapy, not a curated reading list.
Similar pages
not linked directly; found by shared links- TechnologyNK cell therapy and CAR-NK
Shares Allogeneic (off-the-shelf) cell therapy, Acute myeloid leukaemia, CAR-T cell therapy.
- CompanyAllotera Therapeutics (formerly Wugen)
Shares Allogeneic (off-the-shelf) cell therapy, Acute myeloid leukaemia, CAR-T cell therapy.
- CompanyOrca Bio
Shares Allogeneic (off-the-shelf) cell therapy, Acute myeloid leukaemia.
- InstitutionPeking University People's Hospital
Shares Allogeneic (off-the-shelf) cell therapy, Acute myeloid leukaemia, CAR-T cell therapy.
- PersonStephen J. Forman
Shares Allogeneic (off-the-shelf) cell therapy, Acute myeloid leukaemia, CAR-T cell therapy.
- TargetCD7
Shares Allogeneic (off-the-shelf) cell therapy, Acute myeloid leukaemia, CAR-T cell therapy.
- CompanyMendus
Shares Allogeneic (off-the-shelf) cell therapy, Acute myeloid leukaemia.
- CompanyAdicet Bio
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.